arrow_back Back to App

Increased Transparency for Biologics Market

New rules aim to increase transparency regarding the availability of biological medicines on the market. Pharmaceutical companies will need to report more quickly whether their products are available for sale, which can help in better supply planning and avoiding shortages. This ensures citizens have up-to-date and easily accessible information about medicines.
Key points
Companies must promptly report the marketing status of biological products.
A one-time report is required for all biological products to confirm availability or withdrawal from sale.
The "Purple Book" information system for biological products is improved for completeness.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_7035
Sponsor: Rep. Manning, Kathy E. [D-NC-6]
Process start date: 2022-03-09
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Biologics Market Transparency Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_7035.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-09.

What are the main provisions?

Key points include:

  • Companies must promptly report the marketing status of biological products.
  • A one-time report is required for all biological products to confirm availability or withdrawal from sale.
  • The "Purple Book" information system for biological products is improved for completeness.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Manning, Kathy E. [D-NC-6].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health